1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (6210)
  2. Journal Article (5696)
  3. Review (405)
  4. Book Section (186)
  5. Editorial (186)
  6. Research Letter (169)
  7. Guidelines (86)
  8. Conference Paper (65)
  9. Correspondence (58)
  10. Miscellaneous (17)
  11. Book Whole (9)
Groups
  1. Hematologic Malignancies, Division of (13087)
  2. Department of Medicine (13003)
  3. Center for Hematologic Malignancies (10394)
  4. GSK Faculty (4421)
  5. Adult Leukemia (3582)
  6. Bone Marrow Transplant (2776)

More Groups

People
  1. Sergio Giralt (1050)
  2. Miguel-Angel Perales (913)
  3. Ross Levine (774)
  4. Andrew Zelenetz (767)
  5. Martin Tallman (649)
  6. Steven Horwitz (645)

More People

Years
  1. 2025 (203)
  2. 2024 (670)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3371)
  2. Journal of Clinical Oncology (1214)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (328)
  5. Haematologica (289)
  6. Bone Marrow Transplantation (238)

More Publications

Publishers
  1. American Society of Hematology (3638)
  2. Elsevier Inc. (1609)
  3. American Society of Clinical Oncology (1266)
  4. Nature Publishing Group (994)
  5. American Association for Cancer Research (637)
  6. Wiley Blackwell (430)

More Publishers

Results (13087)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Identification of inducers of megakaryocyte polyploidization and their use as targeted differentiation therapy for acute megakaryocytic leukemia
    Meeting Abstract

    Wen, Q.; Huang, Z.; Small, S.; Bubna, N.; An, F.; Bliss-Moreau, M.; Verplank, L.; Lewis, T.; Schenone, M.; Tolliday, N.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Cisplatin-based chemotherapy is associated with an unacceptably high incidence of thromboembolic events: A large retrospective analysis
    Meeting Abstract

    Moore, R. A.; Adel, N. G.; Bhutani, M.; Tabbara, N. E.; Landau, H.; Nimer, S. D.; Feldman, D. R.; Hassoun, H.
    Blood (2009)

    Fulltext@MSK | Save
  • Adjuvant bortezomib and dexamethasone following risk-adapted melphalan and stem cell transplant in systemic light-chain amyloidosis (AL): A phase II study
    Meeting Abstract

    Landau, H.; Hassoun, H.; Cohen, A. D.; Lesokhin, A.; Bello, C.; Hoover, E.; Riedel, E. R.; Ciminiello, J.; McCullagh, E.; Nimer, S. D.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • A phase 1b clinical trial of dacetuzumab in combination with rituximab and gemcitabine: Multiple responses observed in patients with relapsed diffuse large B-cell lymphoma
    Meeting Abstract

    Forero-Torres, A.; Bartlett, N. L.; Nasta, S. D.; Northfelt, D.; Beaven, A.; Myint, H.; Whiting, N. C.; Drachman, J. G.; Moskowitz, C. H.
    Blood (2009)

    Fulltext@MSK | Save
  • R-CHOP, followed by high dose therapy and autologous stem cell rescue (HDT/ASCR), and R-HyperCVAD have equivalent progression-free survival and are superior to R-CHOP alone in younger patients with mantle cell Lymphoma: A comparative effectiveness analysis from the National Comprehensive Cancer Network (NCCN) non-Hodgkin's lymphoma Outcomes Database project
    Meeting Abstract

    LaCasce, A.; Vandergrift, J. L.; Rodriguez, M. A.; Crosby, A. L.; Lepisto, E. M.; Czuczman, M. S.; Nademanee, A. P.; Blayney, D. W.; Gordon, L. I.; Millenson, M.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Necdin regulates hematopoietic stem cell quiescence and sensitivity to genotoxic stress
    Meeting Abstract

    Asai, T.; Liu, Y.; Di Giandomenico, S.; Deblasio, A.; Menendez, S.; Antipin, J.; Reva, B.; Wevrick, R.; Nimer, S. D.
    Blood (2009)

    Fulltext@MSK | Save
  • TRAIL/DR5 interactions are important for thymic damage after allogeneic bone marrow transplantation
    Meeting Abstract

    Na, I. K.; Lu, S. X.; Yim, N. L.; Goldberg, G. L.; Tsai, J.; Rao, U. K.; Smith, O. M.; King, C.; Suh, D.; Hirschhorn-Cymerman, D.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Accelerated total lymphoid irradiation (TLI) as an integral component of high-dose therapy (HDT) salvage regimen for patients with refractory and relapsed Hodgkin lymphoma (HL): 20 years of experience with 186 patients
    Meeting Abstract

    Rimner, A.; Bonner, P.; Gonzales, A. M. R.; Hsu, M.; Zhang, Z.; Moskowitz, C. H.; Yahalom, J.
    International Journal of Radiation Oncology, Biology, Physics (2009)

    Fulltext@MSK | Save
  • Accelerated total lymphoid irradiation (TLI)-containing salvage regimen for patients with refractory and relapsed Hodgkin lymphoma (HL): 20 years outcome with multivariate analysis
    Meeting Abstract

    Rimner, A.; Bonner, P.; Gonzales, A. M. R.; Hsu, M.; Zhang, Z.; Moskowitz, C. H.; Yahalom, J.
    EJC Supplements (2009)

    Fulltext@MSK | Save
  • Multimodality therapy for esophageal cancer
    Book Section

    Ku, G. Y.; Ilson, D. H.
    In Shields, T. W.; LoCicero, J. 3rd; Reed, C. E.; Feins, R. H. (Eds.) General Thoracic Surgery. 7th ed (2009)

    Fulltext@MSK | Save